BioAtla, Inc.

NASDAQ: BCAB · Healthcare · Biotechnology

PublicHQ San Diego, CA · San DiegoCIK 0001826892Reports USD

#975 of 1,422 Healthcare companies by revenue

EA Score

15D

FH 8DQ 20GM —SS 38

v0.1 · 55/100 weight · provisional

↑ workforce scale, market scale · ↓ disclosure history, Piotroski F

Methodology →

Revenue TTM

$8.5M

Rev growth YoY (TTM)

-22.7%

Net income (FY)

-$59.6M

Employees

as of 2026-08-23

Market cap

$5.3M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$300.0k$300.0k2021

Net income-$59.6M-$59.6M2025

Operating income-$59.3M-$59.3M2025

Total assets$13.8M$13.8M2025

Liabilities$50.0M$50.0M2025

Equity-$36.2M-$36.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is BioAtla, Inc.’s revenue?

BioAtla, Inc. booked $300.0k in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -19869.0% net margin.

Peers · Healthcare

Kane Biotech Inc.24D Cannabis Bioscience International Holdings, Inc.18D Nexalin Technology, Inc.34D ABVC BioPharma, Inc.41D Tempest Therapeutics, Inc.24D Motus GI Holdings, Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B60C Sempra$12.4B64C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B88A Illumina, Inc.$4.3B84B+

Key facts

CEOJay Short

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Diego, CA

ExchangeNASDAQ: BCAB

Employees41

IPO date2020-12-16

Latest filings

8-K2026-08-28 10-Q2026-08-13 8-K2026-07-16 DEF 14A2026-06-03 10-Q2026-05-15 8-K2026-04-02 10-K2026-03-31 8-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.